search
Drug Discovery News
Trends
- 1Anthropic Launches Biology Lab in Ambition Beyond AI▼Anthropic's New Biology Lab Signals a Bigger Ambition Than Building AI
Anthropic has opened a new biology lab, a move widely read as a signal that the company's ambitions extend well beyond building artificial intelligence. The initiative suggests Anthropic wants to apply AI capabilities directly to biological research and drug discovery, positioning itself as a player in the life sciences rather than solely a model developer.
- 2
Anthropic has established its own wet laboratory as it expands its AI-driven drug discovery programme, according to Reuters. The lab will let the company test biological hypotheses generated by its AI models in real experiments. Observers see it as a notable step for an AI firm moving from software into hands-on biology and pharmaceutical research.
- 3AI helping scientists advance biological design in health research▼How AI is allowing scientists to advance biological design for health research: HealthLink
Scientists are increasingly using artificial intelligence to speed up biological design for health research, applying AI tools to engineer proteins, model biological systems and accelerate drug and therapy development. The approach is being highlighted as a way to cut research timelines and expand what laboratories can design, with health reporters examining how the technology is changing biomedical science and what it could mean for future treatments.
- 4Why regulatory screening comes after the recipe is done▼Why does regulatory screening happen after the recipe is done?
Drug Discovery News is examining why regulatory screening tends to occur only after a product's formulation, or 'recipe', has already been completed, rather than earlier in development. The question highlights a common tension in drug and food product development, where safety and compliance checks arrive late in the process, potentially forcing costly reformulations when problems are found.
- 510x Genomics Launches Sentira Computational Biology Platform▼10x Genomics Announces Sentira, a New Computational Platform to Turn Complex Biological Data Into Experimental Conclusions
10x Genomics has announced Sentira, a new computational platform designed to transform complex single-cell biological data into experimental conclusions. The company says the tool aims to help researchers interpret large-scale genomics datasets more quickly and reliably, supporting discovery workflows across immunology, oncology and drug development. Announcement details were released via a press statement, with further specifications on availability and features not yet widely reported.
- 6AI-driven therapeutic science: predict, classify, treat●Predict, classify, treat: AI-driven therapeutic science in action
A new science news release highlights how artificial intelligence is being applied to therapeutic research, with the stated approach summarised as predicting disease targets, classifying patient groups and guiding treatment development. The announcement outlines AI-driven methods in drug and therapy discovery, positioning machine learning as a practical tool across the therapeutic pipeline from research through to treatment.